On September 15th, Crest and Oral-B announced the kick off of National Gingivitis Awareness Month, with a press conference in Greeley Square Park, Manhattan, featuring “White Collar” star, Tiffani Thiessen. Thiessen is helping Crest and Oral-B to bring attention to the early gum disease, gingivitis, which affects more than fifty percent of American adults¹. Along with the declaration, Crest and Oral-B are helping consumers prevent and reverse gingivitis by introducing a new member to the Crest® Pro-Health® family, Crest® Pro-Health® Clinical Gum Protection. The new, advanced formula of Clinical Gum Protection provides Crest’s highest level of protection against the plaque bacteria that can cause gingivitis and with regular use, is clinically proven to help reverse gingivitis in just four weeks.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/crestprohealth/44592/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
CVS/pharmacy has kicked-off its ninth annual in-store fund raising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) to help advance ALS research. To date, CVS/pharmacy has raised more than $19 million in its stores—a single $1 donation at a time—to support the funding of new clinical research with the aim of discovering a treatment or cure for this devastating disease. This year's campaign began on June 6 and runs through June 26.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/44466/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
